Trusted Resources: Education
Scientific literature and patient education texts
Improvement in Fine Manual Dexterity in Children With Spinal Muscular Atrophy Type 2 After Nusinersen Injection: A Case Series
source: Children (Basel, Switzerland)
year: 2021
authors: Gu M,Kong HH
summary/abstract:Although nusinersen has been demonstrated to improve motor function in patients with spinal muscular atrophy (SMA), no studies have investigated its effect on fine manual dexterity. The present study aimed to investigate the ability of nusinersen to improve fine manual dexterity in patients with SMA type 2. A total of five patients with SMA type 2 were included. The Hammersmith Functional Motor Scale (expanded version) (HFMSE) and Purdue Pegboard (PP) tests were used to evaluate gross motor function and fine manual dexterity, respectively, until 18 months after nusinersen administration. HFMSE scores improved by 3-10 points (+13-53%) in all patients following nusinersen administration. PP scores also improved in all patients, from 4 to 9 points (+80-225%) in the preferred hand and from 3 to 7 points (+60-500%) in the non-preferred hand. These results suggest that nusinersen treatment improved both gross motor function and fine manual dexterity in children with SMA type 2. Addition of the PP test may aid in evaluating the fine manual dexterity essential for activities of daily living in these patients.
organization: Department of Rehabilitation Medicine, Chungbuk National University Hospital, Cheongju 28644, Korea.DOI: 10.3390/children8111039
read more
Related Content
-
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
-
Patient of the Month: GiannaAfter noticing that her daughter was una...
-
Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated With NusinersenObjective: To retrospectively evaluate t...
-
SMA and Nusinersen (Spinraza) the Story so farhttps://slideplayer.com/slide/14664651/...
-
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
-
Pediatric Spinal Muscular AtrophyWhat is spinal muscular atrophy (SMA)?Sp...
-
Coverage of Genetic Therapies for Spinal Muscular Atrophy Across Fee-for-Service Medicaid ProgramsBackground: Genetic therapies are a prom...